Safety and immunogenicity of a bivalent SARS-CoV-2 recombinant protein vaccine, SCTV01C in unvaccinated adults: A randomized, double-blinded, placebo-controlled, phase I clinical trial-Reference-Cited by-同舟云学术

Safety and immunogenicity of a bivalent SARS-CoV-2 recombinant protein vaccine, SCTV01C in unvaccinated adults: A randomized, double-blinded, placebo-controlled, phase I clinical trial

Published:2023-02 Issue:2 Volume:86 Page:154-225
ISSN:0163-4453
Container-title:Journal of Infection
language:en
Short-container-title:Journal of Infection

Author:

Wang Guiqiang,Zhao Kexin,Han Jun,Hu Zhongyu,Zhang Tianzuo,Wang Yanchao,Shi Rui,Li Yanhua,Song Qinqin,Du Haijun,He Peng,Xu Shuping,Yang Xinjie^ORCID,Fu Yongpan,Cui Yimin,Xie Liangzhi

Funder

Beijing Science and Technology Planning Project

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical)

Reference10 articles.

1. Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: three month analyses of the COV-BOOST trial;Liu;J Infect,2022

2. Development of a thermostable SARS-CoV-2 variant-based bivalent protein vaccine with cross-neutralizing potency against Omicron subvariants;Wang;Virology,2022

3. A bivalent COVID-19 vaccine based on alpha and beta variants elicits potent and broad immune responses in mice against SARS-CoV-2 variants;Wang;Vaccines (Basel),2022

4. Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine;Falsey;N Engl J Med,2021

5. Efficacy and safety of the mRNA-1273 SARS-CoV-2 Vaccine;Baden;N Engl J Med,2021

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of the tetravalent protein COVID-19 vaccine, SCTV01E: a phase 3 double-blind, randomized, placebo-controlled trial;Nature Communications;2024-07-24

2. COVID-19 Vaccines: Where Did We Stand at the End of 2023?;Viruses;2024-01-29

3. Safety and immunogenicity of multivalent SARS-CoV-2 protein vaccines: a randomized phase 3 trial;eClinicalMedicine;2023-10

4. Safety and immunogenicity of a tetravalent and bivalent SARS-CoV-2 protein booster vaccine in men;Nature Communications;2023-07-08